This involves immunosuppression, which is required. That is, medications which are required to prevent the patient from rejecting the new organs. Lung volume reduction surgery, on the other hand, involves removal of small parts of the diseased lung, in hopes of allowing other areas of the lung, which are perhaps less diseased, to function more efficiently, and therefore does not require any immunosuppression or addition of new medications. In fact, in many cases it allows patients to take less medication.
PAUL MONIZ: Why isn't a lung transplant a good option for some patients, especially patients that are in their sixties and seventies?
MICHAEL ARGENZIANO, MD: First of all, the main problem you have with any modality which involves transplantation, is donor supply. There are literally millions of people in this country that suffer from COPD, and there are hundreds of thousands that are probably candidates for a transplant. However, the number of organs is severely limited by the number of donors that are identified.
Specifically with respect to lung transplantation, the lungs are the organs, which are most delicate and which are most difficult to recover in good shape, or at least in good enough shape to be used for transplantation. Beyond that, as you've mentioned, COPD is a disease that strikes the elderly population. For that reason, because the immunosuppressive drugs that we use in transplantation can be problematic and even contraindicated in older patients, they are sometimes not a good combination. For that reason, most centers will not transplant patients that are older than 65 or 70 years of age.